JP Morgan

The Inter-American Development on Tuesday extended its Kangaroo curve with an April 2027 issue. The new bond is, in effect, replacing IADB's June 2026 bond, the borrower said.

St. Louis-headquartered Belden, the communications equipment manufacturer, launched €200m of 10 year non-call five notes on Tuesday morning, as the high yield market looks to maintain issuance momentum following a bumper September.

Nets, the largest Nordic digital payments processing company, has confirmed that Deutsche Bank stabilised its share price after its IPO on September 23, when the company’s share price closed at Dkr145, down 3.3%, on its first day of trading.

Samsung BioLogics Co has started gauging investor interest for an up to W2.25tr ($2bn) IPO on the main Kospi board in South Korea, with bookbuilding set to begin in mid-October.

One of the most regular names in Europe’s equity block trade market, Abertis Infraestructuras, was the subject of another deal on Monday night, with regular bookrunners UBS, Bank of America Merrill Lynch and JP Morgan at the helm.

Italy announced on Monday the banks to lead its first ever 50 year syndication, a bond planned since May.

Gatwick Airport made a rare solo flight into the sterling bond market on Monday as the pound fell on resurgent Brexit fears, but UK investors were present to support the deal.

ConvaTec, the UK medical supplies company, has announced plans for an IPO of at least $1.8bn (£1.4bn) on the London Stock Exchange this autumn in an intention-to-float document issued on Monday morning.

China Merchants Securities Co raised HK$10.7bn ($1.4bn) in its Hong Kong IPO, pricing the shares below the middle of expectations as bankers on the deal voiced differing opinions on its execution.

GE Capital has completed the first sell-down of shares in Moneta Money Bank, the Czech commercial lender, since its Ck20bn (€739m) Prague IPO in May.

Clio Cosmetics Co is eyeing a listing on the Kosdaq to raise up to W184.4bn ($165m), with bookbuilding set to begin in October.

Debut issuer Jubilant Pharma ventured out to the international bond market on September 29, netting $300m from its first dollar-denominated transaction.